SubHero Banner

Lenvima® (lenvatinib) and Keytruda® (pembrolizumab) – New indication

September 17, 2019 - The FDA announced the approval of Eisai’s Lenvima (lenvatinib), used in combination with Merck’s Keytruda (pembrolizumab), for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.

Download PDF